0001209191-23-027942.txt : 20230508 0001209191-23-027942.hdr.sgml : 20230508 20230508162948 ACCESSION NUMBER: 0001209191-23-027942 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230505 FILED AS OF DATE: 20230508 DATE AS OF CHANGE: 20230508 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cook Timothy DeVere CENTRAL INDEX KEY: 0001902974 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38112 FILM NUMBER: 23898206 MAIL ADDRESS: STREET 1: C/O ATHENEX, INC., 1001 MAIN STREET, STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Athenex, Inc. CENTRAL INDEX KEY: 0001300699 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 431985966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 BUSINESS PHONE: 716-898-8625 MAIL ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20131223 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC DATE OF NAME CHANGE: 20040817 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-05 0 0001300699 Athenex, Inc. ATNX 0001902974 Cook Timothy DeVere C/O ATHENEX, INC., 1001 MAIN STREET SUITE 600 BUFFALO NY 14203 0 1 0 0 See Remarks 0 Common Stock 2023-05-05 4 A 0 368 1.36 A 4140 D Stock Option (Right to Buy) 345.80 2022-08-16 2028-08-16 Common Stock 3500 3500 D Stock Option (Right to Buy) 205.20 2030-08-27 Common Stock 1500 1500 D Stock Option (Right to Buy) 71.20 2031-09-16 Common Stock 450 450 D Restricted Stock Units Common Stock 338 338 D Stock Option (Right to Buy) 13.31 2032-07-20 Common Stock 3750 3750 D Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase. This option vests in four equal annual installments beginning on August 27, 2021. This option vests in four equal annual installments beginning on September 16, 2022. Each restricted stock unit represents a contingent right to receive one share of stock. The restricted stock units vest in four equal annual installments beginning on September 16, 2022. This option vests in four equal annual installments beginning on July 20, 2023. Chief Business and Commercial Officer, Proprietary Drugs /s/Steven Adams, Attorney-in-Fact 2023-05-08